Standard BioTools, Inc. (LAB)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$0.69+1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · LAB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 84.6 | 85.3 | 174.4 | 106.3 | 97.9 | 130.6 | 138.1 | 117.2 | 113.0 | 101.9 | 104.4 | 114.7 | 116.5 | 71.2 | 52.3 | 42.9 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 101.9 | 104.4 | 114.7 | 116.5 | 71.2 | 52.3 | 42.9 |
| Cost of Revenues | 41.9 | 42.8 | 90.2 | 55.9 | 60.9 | — | — | 53.0 | 51.3 | — | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | — |
| Gross Profit | 42.7 | 42.5 | 84.3 | 50.5 | 37.1 | — | — | 64.3 | 61.6 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 86.9 | 109.9 | 156.6 | 87.5 | 102.3 | 98.9 | 97.9 | 84.5 | 79.8 | 79.5 | 93.2 | 83.0 | 71.3 | 48.4 | 38.5 | 31.3 |
| R&D Expenses | 18.4 | 26.0 | 62.4 | 25.9 | 37.4 | 37.9 | 36.5 | 31.6 | 30.0 | 30.8 | 38.4 | 39.3 | 43.4 | 20.0 | 16.6 | 13.9 |
| Operating Income | (95.5) | (110.2) | (175.2) | (76.6) | (116.2) | (67.5) | (51.0) | (51.8) | (48.2) | (58.4) | (73.2) | (50.2) | (51.8) | (18.7) | (18.1) | (18.6) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | 4.6 | 4.3 | 3.8 | 3.6 | 4.3 | 13.9 | 5.8 | 5.8 | 5.8 | 5.3 | 0.0 | 0.6 | 3.1 |
| Asset Writedown | — | — | — | — | — | 0.0 | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| EBT, Incl. Unusual Items | (91.0) | (96.7) | (138.3) | (74.2) | (192.9) | (63.7) | (54.1) | (66.7) | (61.4) | (63.8) | (80.2) | (54.8) | (57.7) | (16.4) | (18.9) | (22.3) |
| Income Tax Expense | (37.0) | (37.9) | 0.6 | 0.5 | (2.8) | (4.4) | (1.1) | (1.9) | (2.4) | (3.3) | (4.2) | (1.5) | (4.9) | 0.1 | 0.1 | 0.2 |
| Net Income | ||||||||||||||||
| Net Income | 84.9 | (74.9) | (138.9) | (74.7) | (190.1) | (59.2) | (53.0) | (64.8) | (59.0) | (60.5) | (76.0) | (53.3) | (52.8) | (16.5) | (19.0) | (22.5) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.22 | (0.20) | (0.52) | (0.94) | (2.43) | (0.78) | (0.74) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 0.22 | (0.20) | (0.52) | (0.94) | (2.43) | (0.78) | (0.74) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 0.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 390.9 | 381.6 | 353.2 | 79.2 | 78.3 | 75.8 | 72.0 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 390.9 | 381.6 | 353.2 | 79.2 | 78.3 | 75.8 | 72.0 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (101.0) | (162.9) | (73.2) | (113.4) | (64.2) | (47.0) | (47.2) | (42.8) | (51.0) | (66.5) | (45.2) | (47.8) | (16.1) | (15.9) | (17.2) |
| EBIT | (95.5) | (110.2) | (175.2) | (76.6) | (116.2) | (67.5) | (51.0) | (51.8) | (48.2) | (58.4) | (73.2) | (50.2) | (51.8) | (18.7) | (18.1) | (18.6) |
| Effective Tax Rate | 40.7% | — | — | -0.6% | 1.5% | 6.9% | 2.0% | 2.9% | 3.9% | 5.1% | 5.2% | 2.7% | 8.4% | -0.8% | -0.7% | -0.7% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.